Quick Answer
Yes, Medicare Part B covers Orthovisc injections for knee osteoarthritis when medical necessity criteria are met. Orthovisc is a high molecular weight hyaluronic acid product given as a series of 3 to 4 weekly injections. Most patients pay 20% coinsurance after meeting their Part B deductible.
Medicare Part B Coverage for Orthovisc
Orthovisc is a high molecular weight sodium hyaluronate injection manufactured by DePuy Synthes (a Johnson & Johnson company). It is designed to supplement the natural hyaluronic acid in your knee joint. Medicare covers Orthovisc under Part B (the medical benefit) because it is administered in a physician’s office or outpatient facility.
Key coverage facts:
- Covered under Part B as a physician-administered injectable
- No prior authorization required under Original Medicare
- Subject to Local Coverage Determinations (LCDs) from your regional MAC
- Must meet medical necessity criteria documented in your medical records
- High molecular weight formulation designed for longer-lasting joint lubrication
Coverage Requirements
Medical Necessity Criteria
For Medicare to pay for Orthovisc, your medical records must show:
- Diagnosis of knee osteoarthritis with ICD-10 code M17.x
- Failure of conservative treatment for at least 3 months, including physical therapy, NSAIDs, or activity modification
- Chart documentation confirming that conservative approaches did not give adequate relief
- X-ray evidence confirming osteoarthritis (most MACs require imaging within the past 12 months)
Billing Codes
| Code | Description | 2026 Estimated Allowable |
|---|---|---|
| J7324 | Orthovisc (sodium hyaluronate), per dose | $250 - $350 per injection |
| 20610 | Arthrocentesis, large joint (knee) | $85 - $110 |
| 77002 | Fluoroscopic guidance (if used) | $75 - $95 |
Your provider bills Medicare using J-code J7324 for each Orthovisc injection. Since it is a 3-to-4-injection series, this code is billed for each injection in the treatment course.
Frequency Limits
- Medicare typically covers one treatment course (3-4 weekly injections) per knee every 6 months
- Some MACs allow repeat treatment after 6 months if the initial course provided meaningful clinical improvement
- Bilateral knee treatment is generally covered when both knees have documented OA
- Your provider should document the degree of relief achieved to support repeat courses
Your Out-of-Pocket Costs
| Item | Amount |
|---|---|
| Part B deductible (2026) | $257/year |
| Coinsurance | 20% of Medicare-approved amount |
| Typical total patient cost | $150 - $300 per treatment course |
| With Medigap | May cover the 20% coinsurance |
Example Cost Calculation
If Medicare approves $300 per injection for a 3-injection course ($900 total):
- Medicare pays: $720 (80%)
- You pay: $180 (20%)
- If you have a Medigap plan: your supplement may cover some or all of that $180
Medicare Advantage Plans
If you have a Medicare Advantage (Part C) plan:
- Coverage generally follows Original Medicare guidelines
- Prior authorization may be required — check with your plan before scheduling
- Copays vary by plan and may differ from the standard 20% coinsurance
- Network restrictions may apply — make sure your provider is in-network
- Contact your plan’s member services for coverage details before your appointment
What If Medicare Denies Coverage?
If your Orthovisc claim is denied:
- Request the denial reason in writing
- Gather supporting documents including X-rays, treatment records, and your provider’s letter of medical necessity
- File a redetermination (Level 1 appeal) within 120 days
- Include clinical evidence supporting the medical necessity of Orthovisc for your specific condition
Many initial denials are overturned on appeal when complete documentation is submitted.
Orthovisc Product Details
| Feature | Detail |
|---|---|
| Manufacturer | DePuy Synthes (Johnson & Johnson) |
| Active ingredient | Sodium hyaluronate (ultra-pure, high MW) |
| Injection schedule | 3 to 4 injections, given 1 week apart |
| FDA-approved for | Knee osteoarthritis |
| Molecular weight | 1.0 - 2.9 million daltons (high molecular weight) |
| Source | Avian-derived (chicken comb extract) |
| Volume per injection | 2 mL |
Orthovisc is distinguished by its high molecular weight, which may provide better joint cushioning and longer-lasting viscosity compared to lower molecular weight alternatives. It is manufactured by the same company that produces Monovisc (the single-injection version).
Frequently Asked Questions
How often will Medicare pay for Orthovisc?
Medicare generally covers one Orthovisc treatment course (3 to 4 weekly injections) per knee every 6 months. Your provider should document medical necessity and clinical benefit from prior treatment courses.
Do I need prior authorization for Orthovisc under Medicare?
No. Original Medicare does not require prior authorization for Orthovisc. If you have a Medicare Advantage plan, your plan may require prior authorization. Verify with your plan before scheduling.
Is Orthovisc covered under Medicare Advantage?
Yes. Medicare Advantage plans must cover everything Original Medicare covers. However, your plan may have different cost-sharing, network restrictions, or prior authorization requirements. Contact your plan directly for specifics.
What is the difference between Orthovisc and Monovisc?
Both are made by DePuy Synthes. Orthovisc is given as 3 to 4 weekly injections, while Monovisc is a single injection. The choice between them often comes down to whether you prefer fewer office visits (Monovisc) or a multi-injection approach (Orthovisc). Medicare covers both products.
Does Orthovisc contain animal products?
Yes. Orthovisc is derived from chicken combs. If you have allergies to poultry, feathers, or eggs, let your doctor know. Non-avian alternatives like Euflexxa are available and also covered by Medicare.